Electronic Theses and Dissertations (Masters)

Permanent URI for this collection

https://hdl.handle.net/10539/38221

Browse

Now showing 1 - 20 of 31

A multicentre study to evaluate an in-house multiparameter immunophenotypic panel to identify precursor B-cells in the determination of measurable residual disease in paediatric B-cell acute lymphoblastic leukaemia
(University of the Witwatersrand, Johannesburg, 2024) Nell, Zanre; Glencross, Deborah; Geel, Jennifer
Background: Periodic assessment of measurable residual disease (MRD) is an important prognostic factor in the management of paediatric B-cell acute lymphoblastic leukaemia (ALL). Conventional polymerase chain reaction (cPCR) and multiparameter flow cytometry (MFC) are well-established in MRD determination, the latter with no current optimal immunophenotypic panel by international consensus. Objective: To determine whether an in-house immunophenotypic panel containing the discriminatory CD58-FITC (cluster of differentiation; fluorescein isothiocyanate) marker compares with cPCR in the detection of paediatric B-cell ALL MRD. Methods: This prospective descriptive validation study was performed on diagnostic and follow-up bone marrow aspirate samples, comparing an in-house immunophenotypic panel against the standardised commercial ClearLLab 10CTM B-cell/myeloid cell-2 (M2) panels in MRD assessment. These findings were then compared to cPCR to determine individual panel performance and predictive power. Results: Both immunophenotypic panels demonstrated 100% concordance in the identification of the leukaemia-associated immunophenotype (LAIP) on all diagnostic samples. The in-house immunophenotypic panel showed a higher sensitivity and specificity, and greater association with cPCR in MRD assessment in follow-up samples. In combination with shared backbone markers of the ClearLLab 10CTM B-cell/M2 panels, inclusion of CD58-FITC and CD81-APC-H7 (allophycocyanin- cyanine dye) proved most informative in accurate distinction between regenerating B-cell precursors and residual leukaemic cells. Conclusion: This work confirms the findings of previous studies, where discriminatory marker CD58- FITC in combination with backbone informative markers demonstrates both superior diagnostic and monitoring utility in paediatric B-cell ALL. The in-house immunophenotypic panel offers an attractive, comparable alternative in MRD determination in this patient population whilst awaiting cPCR results, raising the possibility of earlier clinical decision-making with potential improvement of morbidity and mortality outcomes
Verification and implementation of a chromogenic Factor VIII assay to monitor Factor VIII levels in patients with haemophilia A on emicizumab therapy
(University of the Witwatersrand, Johannesburg, 2024) Masia, Tlangelani Vivian
INTRODUCTION: Hemophilia A is an X-linked inherited bleeding disorder traditionally managed with replacement of the deficient clotting factor. A subset of patients however, develops inhibitors to infused FVIII rendering this treatment ineffective. Emicizumab is a novel, non-factor based therapy for patients suffering from hemophilia A with efficacy in the presence of inhibitors. Assessment of FVIII activity in patients on emicizumab treatment however, requires analysis with a chromogenic FVIII reagent such as the TriniCHROM FVIII:C (Stago) assay. METHODS: STAGO® engineers set-up the TriniChrome FVIII:C assay followed by 20 consecutive analyses of normal and pathological TriniChrome FVIII:C controls on both analyzers to assess precision. FVIII levels were measured in 50 samples from patients with (n 15) and without (n 35) hemophilia with a time-to-clot and the TriniCHROM FVIII:C assays to determine agreement between the 2. Samples from 10 patients with hemophilia A known to have FVIII inhibitors who were not exposed to emicizumab were also analyzed for FVIII inhibitor activity with both assays. FVIII levels in 10 patients with hemophilia A on emicizumab therapy were also determined with both assays. These were all for the accuracy study. Results were analyzed with standard statistical methods. RESULTS: Acceptable SD <8 according to the manufacturer and International Council of Standardization in Hematology and % CV <8.4 according to the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) were obtained on both analyzers. Acceptable agreement of FVIII levels between the 2 assays was obtained on the 50 random plasma samples with a linearity coefficient of determination (R²) of 0.92. FVIII inhibitor levels on the 10 samples from patients with known inhibitors were also within the significance category of more than 0.6 Bethesda Units (BUs) with both assays. FVIII levels of patients with severe hemophilia A on emicizumab therapy analyzed with the time-to-clot assay produced measurable results reflecting the endogenous activity of the drug but FVIII results with the chromogenic assay were similar to the patient’s baseline pre-treatment FVIII levels. CONCLUSION: The TriniCHROM FVIII:C assay is compatible with routine automated coagulation analyzers and can be utilised to assess endogenous FVIII and FVIII inhibitor levels in hemophilia A patients on emicizumab therapy
Audit of Lysosomal Storage Diseases Testing at the National Health Laboratory Service in Johannesburg from 2011-2020
(2023) Novellie, Michael
Lysosomal Storage Diseases (LSDs) are a group of Inborn Errors of Metabolism (IEM), due to the lack of a lysosomal enzyme. This results in toxic accumulation of metabolic waste products in various organs leading to neurodevelopmental regression, organ failure and premature death in the absence of treatment. Treatments for LSDs are limited. This study audited LSD diagnostic test requests received by the Division of Human Genetics, National Health Laboratory Service (NHLS) in Johannesburg from 2011 to 2020 with the aim of understanding the demand, appropriateness, and patient management of suspected LSD cases. A quantitative survey of all samples (1861 tests) referred to NHLS Johannesburg during the study period was performed. A total of 198 (13.3%) samples were rejected for testing mainly because of faulty sample collection. Of the 1663 that were accepted for testing 1457 (87.6%) tested negative, 73 (4.4%) were inconclusive and 133 (8.0%) tested positive. Fifty-five (3.1%) patients with LSD test requests, all of which were positive, were known to a Clinical Genetics unit. The most frequently requested test was for Fabry disease: 620 (33.3% of all requests), even though this disease is not the most prevalent LSD. Of the 603 accepted test requests for Fabry disease, only 6 (1.0%) tested positive. This suggests that some referring clinicians had unrealistic expectations of encountering this disease. It should be noted, however, that testing for Fabry disease is part of a broad diagnostic workup that may be applied even if the indication for testing is not specific. Access to LSD testing was unequal: private facilities were proportionally over-represented compared to public facilities; certain provinces with large referral centres (in KZN and Gauteng) were over-represented compared to smaller centres. Feedback and education of referring clinicians regarding indications for testing and importance of patient follow up, especially by clinical genetics services, are recommended. Follow up of positive MPS screening tests with specific diagnostic tests is essential. A system should be implemented where a medical geneticist phones the referring clinician and discusses further sample requirements (blood for enzyme analysis) and referral to a genetics clinic for all positive LSD screening tests. Future consideration should be given to designing a more systematic testing process, with the introduction of molecular testing to supplement biochemical testing.
Rationalising laboratory workflow to improve the efficiency of diagnostic service delivery: A critical review of haematological malignancies by flow cytometric immunophenotyping at the Charlotte Maxeke Johannesburg Academic Hospital
(University of the Witwatersrand, Johannesburg, 2023) Naidoo, Maynolia; Glencross, Debbie
The 2006 Bethesda medical indications guideline provides concise indications for flow cytometric immunophenotyping (FCI), to enable rationalising a decision for sample processing. The local practice of processing every sample received for FCI places an enormous burden on the resources of the laboratory, and leads to unnecessary expenditure for state health. A ‘triage’ process based on the current Bethesda medical indications guideline may be beneficial in developing countries. The aim of this study was to determine how the implementation of a triage process would impact on the diagnostic service delivery, and the ability to detect or miss disease. A retrospective review of 500 bone marrow aspirate (BMA) samples submitted for FCI analysis was performed from October to December 2019. The sensitivity, specificity, and predictive values of the BMA cytomorphology against the FCI outcomes (‘test-all’) were determined. Thereafter, the Bethesda medical indications guideline was retrospectively applied to the same data set (‘triage’), to compare the decision to process or not to process samples, against objective evidence of disease in various BMA investigations. After exclusion of inadequate quality samples that preclude comparison, 429 ‘test-all’ and 455 triage cases were evaluated. The ‘test-all’ analysis revealed a 97.1% sensitivity and 89.8% specificity, with a 64.1% positive predictive value (PPV) but striking 99.4% negative predictive value (NPV). The triage was largely effective in identifying cases with disease, revealing a 100% sensitivity and 83.3% specificity, with a PPV of 32.5% and very high NPV of 93.8%. Without impacting clinical outcomes, the implementation of a triage process can reduce the burden of FCI testing by 18%. Preliminary cytomorphological review of the accompanying BMA is strongly recommended as an additional step to improve the overall PPV of the triage, while safely reducing unnecessary FCI sample processing in a further 56% of cases. The implementation of a triage process with modifications for local use in flow cytometry laboratories, would enable the appropriate rationalisation of resources, improve the cost- effectiveness, and overall diagnostic service delivery in developing countries like Sub-Saharan Africa
Mutation Profiling of Paediatric Solid Tumours in a Cohort of South African Patients
(University of the Witwatersrand, Johannesburg, 2023) Manolas, Erin; Krause, Amanda; Lamola, Lindie
Childhood cancers are an emerging global health burden, with the highest increase in incidence and mortality rates occurring in low-middle income countries, such as South Africa (SA). Adding to this burden is the contribution of cancer-predisposing genes (CPGs), whose germline variants increase the risk of cancer development in childhood. These genes are largely associated with a set of disorders, known as cancer-predisposing syndromes (CPSs), which are characterised by an increased likelihood of cancer development and/or additional phenotypic malignant/non- malignant features. Next-Generation Sequencing (NGS) technologies have been key in determining the occurrence and contribution of such germline variants to paediatric cancer development across international research and diagnostic settings. However, these technologies have not been applied to paediatric cohorts in SA and thus there is a paucity of data regarding the contribution of germline variants to childhood cancer development in this setting. Through the design and evaluation of an NGS targeted-CPG panel, this study aimed to generate germline variant profiles of SA paediatric cancer patients, thereby gaining insight into their potential role in the pathogenesis of childhood cancers. NGS was performed on the genomic DNA from 32 solid-tumour paediatric cancer patients using an Ion Ampliseq 50 CPG panel design and the Ion Torrent S5 sequencing instruments. Germline variants were called using the Ion Torrent Suite™ software (v.5.12.0) and annotated using the Ensembl Variant Effect Predictor. Variants were filtered using a bioinformatics pipeline assessing variant data from population and public databases, computational data, functional studies data, genetic pedigrees indicating family history and phenotypic data. Variant evidence was further interpreted for variant prioritisation and classification according to the ACMG-AMP guidelines. All putative pathogenic/likely-pathogenic (P/LP) variants identified were validated via Sanger Sequencing. Seven pathogenic and/or likely pathogenic germline variants were identified and validated in seven patients. Three of these variants, identified in the NF1, RET, and TP53 genes, were detected in patients who presented with phenotypes consistent with their genetic findings and are associated with well-known CPSs (diagnostic yield - 3/32, ~9.4%). The remaining four variants, identified in the BRCA1, ERCC3, FAH, and RB1 genes, have not been previously associated with the patient’s cancer phenotype and therefore require further investigation. At the time of this project’s data generation, this is the first global report of the novel heterozygous, likely pathogenic FAH p.R162H variant. Additionally, although reported elsewhere, the majority of the variants identified in this study (6/7, ~86.7%) have been reported for the first time within the SA paediatric population. To our knowledge, this is the first study to utilise NGS technologies in the germline variant profiling of paediatric solid-tumour patients in SA and therefore has greatly added to filling the current knowledge gap. In addition, these findings have contributed towards the foundation for the development of a CPG sequencing panel suitable for implementation in a SA diagnostic setting
Genetic characterisation of epidermolysis bullosa in South African patients
(University of the Witwatersrand, Johannesburg, 2024) Vania, Ashira; Dillon, Bronwyn
Background: Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous inherited skin condition, characterised by the formation of blistering skin lesions in response to minimal abrasive skin trauma, with variable additional clinical complications. EB is divided into four subtypes based on histological characteristics: simplex EB (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler syndrome (KS). EB is diagnosed on the basis of family history, and clinical signs and symptoms, in conjunction with histological examination, immunofluorescence mapping and transmission electron microscopy to determine subtype. Where available, molecular genetic testing can identify the causative genetic pathogenic variant/s. There is little recently published research on EB and its genetic aetiology in South African cohorts. The aim of this study was to design a multigene EB panel to investigate the pathogenic genetic variant/s responsible for EB in a group of South African patients, thereby providing information for targeted symptomatic treatment, medical surveillance, and to allow for more accurate genetic counselling and future reproductive options. Methods: Thirteen South African patients with clinically-diagnosed EB were recruited from the genetic clinic in four local State hospitals in Gauteng, South Africa. They were phenotypically characterised in terms of family history of the disorder, clinical features, and histological subtype. Whole exome sequencing was performed and a virtual panel of 11 of the commonly implicated EB-associated genes to screen for pathogenic variants. Genetic variants detected were analysed and classified according to American College of Medical Genetics and Genomics guidelines. Results: The 13 patients all had similar clinical characteristics of generalised skin blistering from birth. Skin biopsy with histopathology examination was available for 7/13 (54%). Histological and electron microscopy investigations correlated with molecular findings in only three cases. A genetic result that either confirmed the clinical diagnosis or supported the clinical diagnosis of EB was found in over half of the study cohort (8/12 (67%)). Three recurring variants were identified; COL7A1 (c.3265C>T), LAMB3 (c.958_1034dup) and LAMB3 (c.1034_1035insGGG; previously unreported). Of the eight patients with a confirmed/supported genetic diagnosis, 50% had JEB and 13% had EBS Conclusion: Of the 13 clinically diagnosed EB patients, 8/13 (67%) could be genetically characterised and three parents had confirmed carrier status; allowing for accurate genetic counselling, in terms of inheritance and recurrence risk information. JEB was seen in a higher frequency and EBS in a lower frequency than would be expected, reflecting a possible ascertainment bias. This study validates the clinical utility of an EB multigene panel for South African patients with EB, with particular focus on COL7A1 and LAMB3
Laboratory Evaluation of Aspergillus Galactomannan Lateral Flow Assays
(University of the Witwatersrand, Johannesburg, 2023) Ubbink, Anja; Chibabhai, Vindana
Invasive aspergillosis diagnosis is based on a combination of clinical, radiological, and mycological factors, including the detection of Aspergillus galactomannan antigen in serum and bronchoalveolar lavage fluid (BALF). Lateral flow assays (LFA) introduced for rapid detection of galactomannan in serum and BALF include the IMMY sōna Aspergillus LFA (IMMY LFA) and the Dynamiker QuicGMTM Aspergillus Galactomannan Ag LFA (QuicGM LFA). Objective To evaluate the performance of the IMMY LFA and QuicGM LFA in South Africa. Methods Serum and BALF samples previously tested by Platelia BioRad Aspergillus GM-EIA were analysed using the two different LFAs. Percentage agreement and precision was assessed. Results Forty-six serum- and 13 BALF samples were tested using the IMMY GM LFA and 48 serum- and 6 BALF samples were tested using the QuicGM LFA. Using an optical density ≥0.5 as positive, results were compared to the BioRad Aspergillus GM-EIA. For the IMMY LFA, serum samples had a positive percent agreement (PPA) of 0% (0/1); negative percent agreement (NPA) of 91% (41/45) and overall percent agreement (OPA) of 89% (41/46). BALF samples had a PPA of 75% (3/4), NPA 50% (5/10) and OPA of 57% (8/14). For the QuicGM LFA, serum samples had a PPA 0% (0/3), NPA of 96% (43/45) and OPA of 90% (43/48). BALF samples had a PPA of 100% (1/1), NPA of 100% (5/5) and OPA of 100% (6/6). For the IMMY LFA, between-day reproducibility for 72% (13/18) and 63% (5/8) for serum and BALF samples, respectively. Between-batch reproducibility was 89% (16/18) and 50% (4/8), respectively for serum and BALF samples. For the QuicGM LFA, between-day reproducibility was 75% (9/12) and 75% (3/4) for the serum and BALF samples, respectively. The between-batch reproducibility was 100% (8/8) for serum and 100% (3/3) for BALF. Conclusion A follow-up evaluation with a larger sample size utilizing clinical, radiological, and laboratory data is warranted to determine the assays’ clinical utility. What this study adds Invasive aspergillosis is a life-threatening disease, where a prompt diagnosis improves outcome. Currently there is no Aspergillus galactomannan assay available in the South African state sector. This study evaluates two lateral flow assays for the detection of Galactomannan in South Africa
Extended characterization of multi-drug resistant organisms colonising neonates at a tertiary hospital in Johannesburg, South Africa.
(2024) Mntla, Nonkululeko Marcia
Neonatal deaths remain high globally, particularly in sub-Saharan Africa. A third of deaths are due to infections, often secondary to multi-drug resistant (MDR) organisms. The purpose of this study was to investigate the prevalence of MDR ESKAPE+ C. auris colonisation amongst hospitalised neonates, to determine risk factors associated with MDR colonisation, and perform antimicrobial resistance characterization of these isolates. Two hundred and fifty-eight swabs were collected from 86 hospitalised neonates at a tertiary South African hospital between November and December 2020. A total of 135 ESKAPE+ C. auris isolates were identified; 68% were MDR. Majority of neonates (65%) were colonised with extended spectrum betalactamase (ESBL) producing Klebsiella pneumoniae, followed by extensivelydrug resistant (XDR) Acinetobacter baumannii. New Delhi metallo-beta-lactamase (NDM) producing A. baumannii were more prevalent than carbapenemase producing Enterobacterales (CPE). A prolonged hospital stay, median=14 days (p<.001) was identified as a risk factor for MDR organism colonisation. The high prevalence of MDR ESKAPE+ C. auris colonisation supports use of non-invasive samples to determine colonisation prevalence. More data are needed to develop improved surveillance systems which should incorporate colonisation swabs and clinical biomarkers in neonates with independently established risk factors.
Colonisation with ESKAPE organisms and Candida auris among primary caregivers and healthcare workers in a neonatal unit at a public sector tertiary South African hospital
(2024) Rees, Nicki
Background: Nosocomial neonatal infection remains a significant cause of mortality and morbidity, particularly in the high care and intensive care settings. Among implicated pathogens ESKAPE- C organisms are considered particularly worrisome due to their virulence, ability to gain resistance and propensity to affect multiple sites. Transmission to neonates is postulated to occur through contact with colonised adults. Objective: This study aims to describe the prevalence of colonisation of both primary caregivers and healthcare workers in contact with admitted neonates. As a secondary objective this study aims to identify the most common resistance patterns in ESKAPE-C organisms isolated from primary caregivers and healthcare workers in a neonatal unit. The overall aim of the study is to provide insight into how best to prevent hospital acquired infections in this group. Methods: This cross-sectional prevalence study describes colonisation of healthcare workers (HCW) and primary caregivers in a neonatal unit in a tertiary South African hospital. Over one week in August 2021, twenty-five primary caregivers and twenty-nine healthcare workers submitted specimens which were processed for the identification of ESKAPE-C organisms. Susceptibility was performed on identified organisms. Results: Of the healthcare worker participants 13,8% (4/29) were shown to be colonised with one or more ESKAPE-C pathogen, while 52% (13/25) of primary caregivers were shown to be colonised with one or more ESKAPE-C pathogens. Of the S. aureus organisms isolated 28,6% were MRSA, of the A. baumannii organisms isolated 66.7% were XDR and of the Enterobacteriaceae isolated 60% were ESBL producing. No CRE or VRE organisms were isolated in this study. Conclusion: This study demonstrates that the prevalence of colonisation of healthcare workers and primary caregivers is significant and reinforces the need for stringent infection prevention and control strategies to prevent transmission to vulnerable neonates.
Machine Learning on biochemical data for the prediction of mutation presence in suspected Familial Hypercholesterolaemia
(2024) Hesse, Reinhardt
Background Familial hypercholesterolemia (FH) is a common monogenic disorder and, if not diagnosed and treated early, results in premature atherosclerotic cardiovascular disease. Most individuals with FH are undiagnosed due to limitations in current screening and diagnostic approaches, but the advent of machine learning (ML) offers a new prospect to identify these individuals. Our objective was to create a ML model from basic lipid profile data with better screening performance than low-density lipoprotein cholesterol (LDL-C) cut-off levels and diagnostic performance comparable to the Dutch Lipid Clinic Network (DLCN) criteria. Methods The ML model was developed using a combination of logistic regression, deep learning and random forest classification and was trained on a 70% split of an internal dataset consisting of 555 individuals clinically suspected of having FH. The performance of the model, as well as that of the LDL-C cut-off and DLCN criteria, were assessed on both the internal 30% testing dataset and a high prevalence external dataset by comparing the area under the receiver operator characteristic (AUROC) curves. All three methodologies were measured against the gold standard of FH diagnosis by mutation identification. Furthermore, the ML model was also tested on two lower prevalence datasets derived from the same external dataset. Results The ML model achieved an AUROC curve of 0.711 on the high prevalence external dataset (n=1376; FH prevalence=64%), which was superior to that of the LDL-C cut off alone (AUROC=0.642) and comparable to that of the DLCN criteria (AUROC=0.705). The model performed even better when tested on the medium prevalence (n=2655; FH prevalence=20%) and low prevalence (n=1616; FH prevalence=1%) datasets, with AUROC curve values of 0.801 and 0.856 respectively. Conclusions Despite the absence of clinical information, the ML model was better at correctly identifying genetically confirmed FH in a cohort of individuals suspected of having FH than the LDL-C cut-off tool and comparable to the DLCN criteria. The same ML model performed even better when tested on two cohorts with lower FH prevalence. The application of ML is therefore a promising tool in both the screening for, and diagnosis of, individuals with FH.
Comparison between lupus nephritis in HIV positive patients and HIV associated immune complex glomerulonephritis with “lupus–like” features: a clinicopathologic study
(2024) Mathaba, Margaret Masala
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease seen commonly in black females of childbearing age. More than half of the patients present with renal disease or lupus nephritis complications. Coinfection with HIV in patients with lupus nephritis is rare. Despite Africa having the highest rate of HIV infection in the world, and there is no available data on the coexistence of HIV and Lupus nephritis. HIV is associated with a wide spectrum of renal diseases, including “lupus-like” HIV-Associated Immune Complex Kidney Disease (HIVICK). The most prevalent renal lesions in “lupus-like” HIVICK is diffuse proliferative lupus nephritis Objectives: This study aimed to compare and correlate the demographics, epidemiology, pathological and clinical findings of HIV positive patients with lupus nephritis and those with “lupus-like” HIVICK. Methods: This retrospective chart review study was conducted at the Charlotte Maxeke Johannesburg Academic Hospital in 5 years (2014-2018). We reviewed case reports that met our criteria for cases with lupus nephritis and cases with “lupus-like” HIVICK and allocated a lupus class according to the report findings. Results: Out of 2174 renal reports, 25(1.14%) patients were diagnosed with lupus nephritis and nine (0.41%) with “lupus-like” HIVICK. There were significant differences in age, serology (urea and creatinine), clinical presentation and lupus class. Conclusion: The occurrence of both HIV associated lupus nephritis and ‘lupus like’ HIVICK is rare. In our setting, the former is more common than the latter. We observed clinical and pathological differences which may be used to diagnose these disease entities.
Delineating the ontogeny of an N332-directed anti-HIV-1 broadly neutralising antibody lineage
(2024) Naidoo, Thamara
Broadly neutralising antibodies (bNAbs) develop in chronically HIV-1 infected individuals and can neutralise a variety of HIV-1 Env strains, making them an important element contributing to the design of HIV-1 vaccines. By understanding and delineating the long affinity maturation pathways that bNAb lineages follow against evolving viruses, it is hoped that this process will be able to be replicated in uninfected people with a series of vaccine immunogens. Investigating the ontogeny of a N332-directed bNAb lineage will provide insights into the key somatic hypermutations necessary for the development of neutralisation breadth. CAP255.G3 is an N332-directed bNAb isolated from CAP255, a participant in the CAPRISA 002 cohort, at 149 weeks post-infection (wpi). Six key antibody intermediates were selected from the CAP255.G3 lineage arm between 17 and 47 wpi, based on their position on a phylogenetic tree and because they contained mutations that were present in broad members of the lineage. We hypothesized that these intermediates would exhibit breadth similar to CAP255.G3. The intermediates were tested against a panel of eight autologous and six heterologous pseudoviruses using a TZM-bl neutralisation assay. The sequence identity of the first heavy chain complementarity-determining region (CDRH1) of CAP255.G3 differed from the closest intermediate and therefore, a CDRH1 chimera was constructed to determine if the CDRH1 from CAP255.G3 affected neutralisation activity. Later intermediates from 39 and 47 wpi, had moderate neutralisation activity against the autologous pseudoviruses, but only theintermediate closest to CAP255.G3 had limited neutralising activity against the heterologous pseudoviruses. Although the CDRH1 chimera had increased neutralisation activity against the heterologous viruses relative to the intermediates, it was less broad and potent than CAP255.G3. This indicates that additional affinity maturation between 47 and 149 wpi, at sites outside of the CDRH1, was required for the development of neutralisation breadth in the CAP255.G3 lineage arm..
Off-label evaluation of alternative specimen types: Cobas® plasma separation card for HIV viral load and dried blood spots for COVID-19 serology testing
(2024) Mampa, Thabiso Mmammitsi
Plasma is the preferred specimen for HIV viral load (VL) monitoring and COVID-19 serology testing but poses a challenge in resource-limited settings due to the need for venous blood, skilled phlebotomy, and cold storage for specimen integrity. In this study dried blood spots and novel plasma separation devices (PSC, HSSE, and VLPlasma) versus plasma were investigated as alternative specimen types. The plasma separation devices (PSD) were compared to DBS to determine if eliminating cellassociated nucleic acids could improve HIV VL performance. Paired PSD (n=72), DBS (n=72) and plasma (n=72) were prepared from HIV positive residual whole blood. Similarly, paired PSC, DBS (n=91) and plasma (n=91) were prepared from HIV positive prospective whole blood to assess PSC as an alternative specimen for use on the Abbott m2000. The eluates were processed on the GeneXpert (residual blood), Abbott m2000 (residual and prospective blood) and Roche cobas® 68/8800 (prospective blood). Using plasma as reference, residual blood: DBS outperformed PSC, HSSE and VLPlasma in terms of accuracy 91.8%, compared to 87.8%, 79.1% and 75%. Prospective blood: PSC had improved performance over DBS in terms of sensitivity (92.2% and 87.1%), specificity (65% and 61.9%), and accuracy (86.9% and 80.7%). Additionally, the performance of DBS was evaluated for COVID-19 serology testing in 45 PCR-confirmed, COVID-19 positive individuals by preparing laboratory paired DBS-plasma samples. DBS were eluted using two diluents followed by manual ELISA and results compared to reference plasma testing. DBS-PBS and DBS-manufacturer’s diluent showed the same accuracy (93.6%). Kappa values (0.817 and 0.845) and sensitivity (100% and 91.4%) were similar, but DBS-PBS showed low specificity (75%) compared to DBS-diluent (100%). Off-Label use of the cobas® PSC for HIV VL and DBS for COVID-19 serology testing provides expanded options for testing in resource-limited settings. Further evaluation on capillary blood and automated laboratory workflow optimisation would still be required prior to scaled implementation.
Exploring the interaction of host genetics and the gut microbiome in obesity in an African population
(2024) Schnell, Samantha Susan
Obesity is a highly prevalent health concern that is on the rise in Sub-Saharan Africa. Even though genetic variation and gut microbiota have been implicated in the development of obesity independently, the interactions between these factors have not been previously explored in a South African cohort. This study aimed to identify possible associations between host genomes, body mass index as a measure of obesity, and gut microbiota composition (in the form of V3-V4 16S rRNA sequencing) in a female African cohort. Polygenic risk scores predictive of body mass index in this cohort were generated to categorise the participants into high- and low-risk groups. Subsequently, several statistical analyses were performed comparing gut microbiota between these groups. High-risk participants with high body mass index had associations identified with increased abundances of Prevotella_9 and VadinBE97. In contrast, the low polygenic risk and low body mass index sub-group was associated with greater Bacteroides levels. This study acknowledges the plausible interactions between these factors in an African cohort.
The use of insecticide treated eave ribbons as a protection tool against pyrethroid-resistant populations of mosquitoes that transmit malaria and dengue fever
(2024) Shirima, Ruth Severin
Vector control methods such as insecticide treated nets (ITNs) and indoor residual spraying (IRS) have been successful in preventing mosquito-borne diseases like malaria and dengue. However, these methods face challenges including insecticide resistance, high costs, logistical difficulties, low adoption rates, and limited durability. Therefore, there is a need for simpler and more affordable interventions that can be used on a large scale in disease-endemic communities to supplement current approaches. This study evaluated the effectiveness of using insecticide-treated eave ribbons as a potential tool for complementing the current vector control methods. Eave ribbons are pieces of hessian fabric that can be placed around the eave spaces of poorly constructed houses to kill or repel mosquitoes. Laboratory cone bioassays were conducted to assess the efficacy of eave ribbons treated with the organophosphate, pirimiphos-methyl, for killing the malaria vectors, Anopheles funestus and Anopheles arabiensis, and the dengue vector, Aedes aegypti, under varying exposure durations and insecticide doses. In addition, a semi-field experiment was done to assess the efficacy of eave ribbons treated with pirimiphosmethyl against the malaria vectors. Indoor and outdoor biting was assessed by the number of mosquitoes captured indoors in window exit traps and outdoors by human landing catches, respectively. Mortality of recaptured mosquitoes was recorded after 24, 48, and 72 hours. The findings revealed that treated eave ribbons resulted in higher mosquito mortality than the untreated ribbons, but the impact increased with increased exposure duration or dose. The semi-field study indicated moderate levels of bite prevention and mortality of the mosquitoes. At the doses of 1 g a.i./m2 and 2 g a.i./m2 pirimiphos-methyl, there was no significant protection against An. arabiensis, but at the dose of 4 g a.i./m2 pirimiphos-methyl, there was only significant protection against outdoor biting An. arabiensis, but not An. funestus. In conclusion, while insecticide-treated eave ribbons may have potential for controlling malaria and dengue vectors, further research is needed to validate their efficacy in field settings and to identify suitable insecticides or insecticide combinations that are safe and effective.
Characterisation of variation in the CYP2C19 gene in African populations
(2024) Booyse, Ross Peter
Background: CYP2C19 pharmacogenetic testing is important clinically to optimise patient response to clopidogrel and anti-depressants. This study aimed to characterise the distribution of CYP2C19 star alleles (haplotypes) across diverse African populations compared with global populations, with a view towards informing future pharmacogenetic implementations. Methods: CYP2C19 star alleles and diplotypes were called from 604 high coverage genomes from continental African populations using the StellarPGx pipeline. Results: From our analysis, CYP2C19*1 (51%), *2 (17%), and *17 (22%) were the most common star alleles across African populations in this study. We also identified 3% of African participants that had potentially novel CYP2C19 haplotypes. Over 70% of the SSA participants had either poor, intermediate, rapid, and ultrarapid metabolizer status, and would likely benefit from dosage and/or treatment alterations, especially for clopidogrel Conclusion: This study supports the necessity for CYP2C19 pharmacogenetic testing in African clinical settings and the importance of comprehensive star allele characterisation in the African context.
Delineating antibody responses elicited by four SARSCoV-2 variants against the Mu variant
(2024) Kgagudi, Prudence
SARS-CoV-2 is the causative agent of the acute respiratory syndrome known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2 spike protein plays an essential role in virus attachment, fusion and entry and is the main target of neutralizing antibodies. Continued evolution of the spike has led to the emergence of variants of concern or interest (VOC/VOIs) which pose a greater risk to the population due to augmented transmission risk, increased disease severity, antigenic escape and/or decreased effectiveness of vaccines. The Mu variant was first identified in Columbia in January 2021, however the immune escape potential of the variant remains poorly characterised. It is typified by T95I, Y144S and Y145N mutations in the N-terminal domain; R346K, E484K, and N501Y mutations in the receptor-binding domain and D614G, P681H, and D950N mutations in the S2 region. This study aimed to assess targeting of the Mu variant by neutralizing and non-neutralizing antibodies elicited by four variants during four COVID-19 waves in South Africa namely D614G, Beta, Delta and Omicron (BA.1). This was achieved by measuring antibody binding, neutralization and antibody dependent cellular cytotoxicity (ADCC) activity against Mu, and comparing these responses across each of the four variants tested. All variants elicited cross-reactive binding antibodies to Mu although the magnitude of binding to Mu was reduced. This cross-reactivity was a result of multiple binding antibody epitopes on the spike protein. We observed variable neutralization escape of Mu from antibodies triggered by infection with WT D614G and Delta. Antibodies induced by the Beta variant exhibited increased breadth towards the Mu variant when compared to those elicited by other variants. Neutralization escape of Mu from antibodies elicited by WT D614G and Delta may be caused by the 95I, 484K and 346K mutations in Mu, which are known to confer resistance in other variants. Compared to neutralization, ADCC was mostly preserved against Mu. However, the infecting variant impacted the potency of ADCC responses. WT D614G triggered significantly higher ADCC activity against Mu compared to Beta, Delta and Omicron. These data suggest that different variants trigger qualitatively different neutralizing and Fc effector responses, providing a rationale to study humoral resistance following infection by different variants. As Mu shares mutations with other VOCs, this study may aid in predicting the impact of mutations that may be common to emerging VOCs
Characterisation of RSV fusion proteins from South African patients with RSV disease, 2019 to 2020
(2024) Mabilo, Prince
Respiratory syncytial virus (RSV) is classified into subtypes A (RSV-A) and B (RSV-B), which are classified into different genotypes based on genetic variability of the G surface glycoprotein gene. The F surface protein gene is more conserved however variability in signal peptide, transmembrane domain, and antigenic sites have been reported. The study was conducted in the Virology laboratory, Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), South Africa. Study participants included patients of all ages from whom respiratory samples were submitted for respiratory viruses diagnoses from 2019 to 2020. The complete RSV F genes were amplified, library prep was preformed using the Nextera DNA prep kits and sequenced using amplicon-based next generation sequencing on the Illumina MiSeq sequencing platform. The Genome Detective Virus tool v2.27 was used to assemble sequencing reads and MEGA X was used for phylogenetic analysis. N-linked glycosylation and amino acid sequence variation was assessed. The overall prevalence of RSV was 5.8% (101/1 734). Seventy (69.3%; 70/101) RSV-positive samples were available for genetic characterisation of the F protein gene and thirty-one (30.7%; 31/101) were excluded due to insufficient sample volume. Only RSV-A strains were identified (91.2%; 31/34). Twenty three of thirty-one (74.2%) of the RSV F gene sequences from 2019 to 2020 clustered together with bootstrap values ranging from 64% to 99% and were NA1-like. A N-glycosylation site at position 120 gained by South African strains from 2018 is retained in strains from this study. This N-glycosylation site is present in approximately 25.8% of RSV strains from this study. The diversity of RSV-A F proteins was low, with amino acid variations observed at 30/571 (5.3%) sites. Ten mutations were detected in 4/6 antigenic sites (I, II, IV and V), with frequencies ranging from 0.3 to 100%. Antigenic changes seen exclusively among South African strains are: Y33H (0.3%) and V384T (7.3%) at site I and S275F (0.3%) at site II. Seven mutations associated with escape of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocyte (CTL) were predicted in seven epitopes. Overall amino acid mutation frequency for 2019 to 2020 RSV-A F genes is similar to that reported for South African strains from 2018 (3.3% to 6.7%). For the first time in South Africa we detected the S275F mutation which causes palivizumab resistance.
Natural killer cell phenotypic, functional, and nutrient transporter profiles during spontaneous control of HIV-1 infection in black South Africans
(2024) Batohi, Nikayla
Despite the devastation caused by the human immunodeficiency virus (HIV) for over four decades, a subset of individuals termed HIV-1 elite controllers (ECs) can control the virus in the absence of antiretroviral therapy (ART) and may provide a model for a functional cure. This study aimed to understand the role of natural killer (NK) cells as important innate effector cells in the control of HIV-1 infection in African populations. We measured the phenotypic, functional, and nutrient transporter profiles of NK cells on cryopreserved peripheral mononuclear cells from HIV-1 ECs (n=15), viraemic progressors (VPs) (n=19), antiretroviral therapy-treated individuals (ART-treated) (n=20), and HIV-1 uninfected donors (HCs) (n=21) from Johannesburg, South Africa using multicolour flow cytometry. Functional and metabolic profiles were assessed after stimulation with a major histocompatibility complex-devoid cell line. The frequency of NK cells and their subsets in ECs were similar to HCs and ART-treated and altered compared to VPs. Total NK cells in ECs had similar expression of NKG2A (inhibition), NKG2C (activation), PD-1 (exhaustion), and CD57 (maturation) markers compared to ART-treated and increased expression of CD38 and CD69 (activation markers) compared to ART-treated individuals. CD107a (cytotoxicity) was reduced in total NK cells in all people living with HIV-1 compared to HCs, whereas IFN-γ (cytokine production) was comparable across the ECs, HCs, and ART-treated groups and significantly lower in VPs compared to the other study groups. Metabolic profiles (glucose transporter 1 (Glut1), CD98, and CD71) were similar in ECs compared to ART-treated and significantly increased in VPs compared to other study groups. Together these findings show that NK cells from ECs have an inhibitory, mature profile with low levels of immune exhaustion and reduced metabolic phenotype suggesting functional competence. These new insights could be employed in novel immunotherapeutic strategies for the treatment of HIV-1 in an African population.
Evaluating the clinical utility of a SNP-based microarray platform: a comparative study
(2024) Mayisela, Minenhle Peniel
Developmental disorders make up a majority of cases seen in genetic clinics at the National Health Laboratory Service (NHLS). Chromosomal microarray analysis (CMA) is the first line testing for individuals with developmental disorders and congenital anomalies. This study compared the clinical utility of single nucleotide polymorphism (SNP) - based array (CytoScan® Optima array) and a comparative genomic hybridization (CGH) array (SurePrint G3 Unrestricted CGH ISCA v2, 8x60 kb microarray) in diagnosis of developmental disorders. This was done by looking at the differences in copy number variant calls, segment size differences and gene content between the two microarrays. The cost to run each type of microarray test for diagnosis was also compared. The copy number variant calls made by the two platforms were comparable. The SNP-based array did provide additional information that would be useful in molecular diagnosis. The final recommendation was for the CGH array and the SNP-based array to be used interchangeably based on clinical requests at the Division of Human Genetics

Browse

Recent Submissions